Global Information
회사소개 | 문의 | 비교리스트

버크홀데리아 감염증 : 파이프라인 리뷰

Burkholderia Infections - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 293881
페이지 정보 영문 75 Pages
가격
US $ 2,000 ₩ 2,408,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,816,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,224,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


버크홀데리아 감염증 : 파이프라인 리뷰 Burkholderia Infections - Pipeline Review, H2 2016
발행일 : 2016년 12월 페이지 정보 : 영문 75 Pages

버크홀데리아 감염증은 버크홀데리아 세파시아균에 의해 발병하는 감염증으로, 미열에서 시작하여 폐렴, 기침, 울혈, 호흡곤란, 그르렁거리는 호흡 등의 증상으로 이어집니다. 발병 원인은 면역체계 저하와 폐질환 등이며, 치료에는 항생제가 사용됩니다.

버크홀데리아 감염증(Burkholderia Infections) 치료제의 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등에 대한 정보를 전해드립니다.

목차

서론

버크홀데리아 감염증 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

개발중인 치료제 : 기업별

연구중인 치료제 : 대학/연구기관별

파이프라인 제품 개요

  • 임상시험 단계 제품
  • 초기 단계 제품
  • 개발 단계가 불명확한 제품

개발중인 제품 : 기업별

연구중인 제품 : 대학/연구기관별

치료제 개발에 참여하고 있는 기업

  • Arno Therapeutics, Inc.
  • Bavarian Nordic A/S
  • Emergent BioSolutions Inc.
  • Eumedica SA
  • Grifols, S.A.
  • NanoBio Corporation
  • Sarepta Therapeutics, Inc.
  • Soligenix, Inc.
  • Syntiron LLC
  • TGV-Laboratories
  • Vault Pharma Inc.

치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

약제 개요

휴지 상태인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 주목 정보와 프레스 릴리스

부록

도표

LSH 16.09.30

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia Infections - Pipeline Review, H2 2016, provides an overview of the Burkholderia Infections (Infectious Disease) pipeline landscape.

Burkholderia infections are caused by Burkholderia cepacia bacteria. Symptoms include low-grade fever, progressing to much more serious conditions, including pneumonia, cough, congestion, shortness of breath, and wheezing. Predisposing factors include weakened immune system and lung diseases. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burkholderia Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Burkholderia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burkholderia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Burkholderia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Burkholderia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Burkholderia Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Burkholderia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Burkholderia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Burkholderia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Burkholderia Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Burkholderia Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Burkholderia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Burkholderia Infections Overview
  • Therapeutics Development
    • Pipeline Products for Burkholderia Infections - Overview
    • Pipeline Products for Burkholderia Infections - Comparative Analysis
  • Burkholderia Infections - Therapeutics under Development by Companies
  • Burkholderia Infections - Therapeutics under Investigation by Universities/Institutes
  • Burkholderia Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Burkholderia Infections - Products under Development by Companies
  • Burkholderia Infections - Products under Investigation by Universities/Institutes
  • Burkholderia Infections - Companies Involved in Therapeutics Development
    • Aridis Pharmaceuticals LLC
    • Arno Therapeutics Inc
    • Bavarian Nordic A/S
    • Emergent BioSolutions Inc
    • Eumedica SA
    • Grifols SA
    • Sarepta Therapeutics Inc
    • Soligenix Inc
    • Syntiron LLC
    • TGV-Laboratories
    • Vault Pharma Inc
  • Burkholderia Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Inhibit Nucleoporin p62 for Burkholderia Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AR-13 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARD-3100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARD-3150 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Burkholderia pseudomallei vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Burkholderia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Burkholderia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dusquetide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EV-035 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GC-072 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melioidosis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Mul-1867 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Panaecin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SGX-943 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • temocillin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPI-231 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Burkholderia Infections - Dormant Projects
  • Burkholderia Infections - Discontinued Products
  • Burkholderia Infections - Product Development Milestones
    • Featured News & Press Releases
      • May 31, 2016: FDA Grants Soligenix "Fast Track" Designation for SGX943 for the Treatment of Melioidosis
      • Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
      • Aug 14, 2014: US DTRA to fund preclinical work on Evolva's antibiotic GC-072
      • Feb 21, 2014: Bavarian Nordic's MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development
      • Feb 21, 2014: Bavarian Nordic's MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development
      • Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
      • Sep 10, 2012: Evolva Presents Preclinical Data On EV-035 At ICAAC
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Burkholderia Infections, H2 2016
  • Number of Products under Development for Burkholderia Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Burkholderia Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
  • Burkholderia Infections - Pipeline by Arno Therapeutics Inc, H2 2016
  • Burkholderia Infections - Pipeline by Bavarian Nordic A/S, H2 2016
  • Burkholderia Infections - Pipeline by Emergent BioSolutions Inc, H2 2016
  • Burkholderia Infections - Pipeline by Eumedica SA, H2 2016
  • Burkholderia Infections - Pipeline by Grifols SA, H2 2016
  • Burkholderia Infections - Pipeline by Sarepta Therapeutics Inc, H2 2016
  • Burkholderia Infections - Pipeline by Soligenix Inc, H2 2016
  • Burkholderia Infections - Pipeline by Syntiron LLC, H2 2016
  • Burkholderia Infections - Pipeline by TGV-Laboratories, H2 2016
  • Burkholderia Infections - Pipeline by Vault Pharma Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Burkholderia Infections - Dormant Projects, H2 2016
  • Burkholderia Infections - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Burkholderia Infections, H2 2016
  • Number of Products under Development for Burkholderia Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top
전화 문의
F A Q